Details of the Drug Combinations

General Information of This Drug (ID: DMX9V8K)

Drug Name

CONTIGOSIDE B DMX9V8K

Synonyms

Isoquercitrin; Isoquercetin; 482-35-9; Hirsutrin; 3-Glucosylquercetin; Glucosyl 3-quercetin; Quercetin 3-glucoside; Quercetol 3-glucoside; Quercetin 3-o-glucopyranoside; Quercetin 3-D-glucoside; Quercetol 3-monoglucoside; Quercetin 3-monoglucoside; Isotrifoliin; Quercetin 3-beta-glucoside; Quercetin 3-O-glucoside; quercetin-3-glucoside; Quercetin 3-beta-O-glucoside; Quercetin-3-O-glucopyranoside; UNII-6HN2PC637T; quercetin-3-O-glucoside; NSC 115918; BRN 0100989; CHEMBL250450; 6HN2PC637T; CHEBI:68352; quercetin 3-O-beta-D-glucopyran

Indication

Disease Entry	ICD 11	Status	REF
Thrombosis	DB61-GB90	Phase 2/3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Sunitinib + Contigoside B	DCIQJHS	Sunitinib	Renal Cell Carcinoma	[2]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT02446795) Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial